![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CD84 |
Gene summary for CD84 |
![]() |
Gene information | Species | Human | Gene symbol | CD84 | Gene ID | 8832 |
Gene name | CD84 molecule | |
Gene Alias | LY9B | |
Cytomap | 1q23.3 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q9UIB8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8832 | CD84 | HCC1 | Human | Liver | HCC | 4.71e-17 | 2.23e+00 | 0.5336 |
8832 | CD84 | HCC2 | Human | Liver | HCC | 7.20e-38 | 2.45e+00 | 0.5341 |
8832 | CD84 | HCC5 | Human | Liver | HCC | 4.33e-43 | 2.98e+00 | 0.4932 |
8832 | CD84 | Pt14.d | Human | Liver | HCC | 5.45e-04 | 2.41e-01 | 0.0143 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005165621 | Liver | HCC | establishment of organelle localization | 226/7958 | 390/18723 | 4.15e-10 | 1.34e-08 | 226 |
GO:0050777 | Liver | HCC | negative regulation of immune response | 101/7958 | 194/18723 | 4.40e-03 | 1.90e-02 | 101 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD84 | SNV | Missense_Mutation | novel | c.103N>C | p.Glu35Gln | p.E35Q | Q9UIB8 | protein_coding | deleterious(0.02) | probably_damaging(0.98) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
CD84 | SNV | Missense_Mutation | c.67G>A | p.Asp23Asn | p.D23N | Q9UIB8 | protein_coding | tolerated(0.39) | benign(0.009) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
CD84 | SNV | Missense_Mutation | rs753673028 | c.752G>T | p.Arg251Ile | p.R251I | Q9UIB8 | protein_coding | deleterious(0) | possibly_damaging(0.823) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CD84 | SNV | Missense_Mutation | c.919T>A | p.Ser307Thr | p.S307T | Q9UIB8 | protein_coding | tolerated(0.72) | benign(0) | TCGA-C8-A12W-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
CD84 | insertion | Frame_Shift_Ins | novel | c.854_855insTTGTGACTGGAGGT | p.Arg286CysfsTer5 | p.R286Cfs*5 | Q9UIB8 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
CD84 | insertion | Nonsense_Mutation | novel | c.412_413insTTTCCTGAGAAT | p.Thr138delinsIleSerTerGluSer | p.T138delinsIS*ES | Q9UIB8 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
CD84 | insertion | Frame_Shift_Ins | novel | c.412_413insT | p.Thr138IlefsTer13 | p.T138Ifs*13 | Q9UIB8 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
CD84 | insertion | Frame_Shift_Ins | novel | c.411_412insGA | p.Thr138GlufsTer5 | p.T138Efs*5 | Q9UIB8 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
CD84 | SNV | Missense_Mutation | rs544642873 | c.50C>T | p.Pro17Leu | p.P17L | Q9UIB8 | protein_coding | tolerated(0.29) | benign(0) | TCGA-C5-A1MQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
CD84 | SNV | Missense_Mutation | novel | c.1024G>A | p.Glu342Lys | p.E342K | Q9UIB8 | protein_coding | deleterious(0.03) | benign(0.411) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8832 | CD84 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | etanercept | ETANERCEPT | 27564082 |
Page: 1 |